Venus Remedies has entered Singapore's topical pain management market with a marketing authorisation and patent for its herbal nanotechnologybased pain reliever Trois. The company is holding talks with various pharmaceutical firms for tieups to market Trois in Singapore.

It is a great opportunity for the company to capture a sizeable share in this segment of the singapore pharma market. Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffers from symptoms of osteoarthritis.

The worldwide size of the topical pain management market is USD 4 billion, and, going by global projections, Trois has the potential of becoming a USD 250-million product once launched internationa llV.

A product for topical use, Trois provides quick and lasting relief to patients suffering from rheumatic disorders, low back pain, osteoarthritis, rheumatoid arthritis, gout and knee pain, ankylosing spondylitis, fibromyalgia and pain originating from muscles and tendons.  Currently, more than L.5 billion people worldwide suffer from chronic pains of varying degree.

Trois is the safest known topical product for management of pain and inflammation associated with rheumatic disorders. lt is 30% more effective than conventional products, as proven through a series of toxicity and safety studies. lt has 150% enhanced retention for longer effect, improved relief and better mobility.

Shares of the company declined Rs 17.35, or 6.28%, to trade at Rs 259. The total volume of shares traded was 92,124 at the BSE (11.44 a.m., Thursday).